Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma
- PMID: 9917503
- DOI: 10.3892/ijo.14.2.281
Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma
Abstract
Protein induced vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) have been considered useful serum markers of hepatocellular carcinoma (HCC). In this study, we examined the clinicopathologic significance of these tumour markers in patients with HCCs by measuring their serum levels and performing immunohistochemistry. We studied 349 Japanese patients with HCCs. Their serum PIVKA-II and AFP levels were determined by enzyme immunoassay before treatment. We examined the correlations between serum PIVKA-II and AFP levels and tumour size, presence of satellite nodules, histologic HCC grade, and concomitant liver diseases and subjected tumour tissues to immunohistochemical staining to detect PIVKA-II and AFP expression. The serum PIVKA-II levels of patients with poorly differentiated HCCs were significantly higher than those of patients with well and moderately differentiated HCCs (p<0.05) and they were higher in HCC patients with than without satellite nodules. The serum AFP levels were influenced significantly by concomitant liver diseases, but not by the other factors. Immunohistochemical staining revealed the PIVKA-II expression levels of poorly differentiated HCCs were higher than those of well and moderately differentiated HCCs (p<0.05). Some HCC cells were PIVKA-II-positive, others were AFP-positive, and some expressed both. The serum PIVKA-II concentration was a better indicator of HCC than AFP, as it was not influenced by concomitant liver diseases. The presence of PIVKA-II in serum correlated with the presence of satellite nodules and the histologic HCC grade, a result concordant with the immunohistochemical findings.
Similar articles
-
Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.Hepatology. 2001 Dec;34(6):1128-34. doi: 10.1053/jhep.2001.29202. Hepatology. 2001. PMID: 11732002
-
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.Scand J Gastroenterol. 2018 Jun;53(6):734-740. doi: 10.1080/00365521.2018.1459824. Epub 2018 Apr 18. Scand J Gastroenterol. 2018. PMID: 29667463
-
Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.World J Gastroenterol. 2019 Sep 28;25(36):5515-5529. doi: 10.3748/wjg.v25.i36.5515. World J Gastroenterol. 2019. PMID: 31576097 Free PMC article.
-
Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):487-495. doi: 10.1016/j.hbpd.2018.09.009. Epub 2018 Sep 15. Hepatobiliary Pancreat Dis Int. 2018. PMID: 30257796
-
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30. Clin Mol Hepatol. 2023. PMID: 36710606 Free PMC article. Review.
Cited by
-
Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP).J Gastroenterol. 2006 Oct;41(10):1011-9. doi: 10.1007/s00535-006-1889-8. Epub 2006 Nov 9. J Gastroenterol. 2006. PMID: 17096071
-
Present and future possibilities for early diagnosis of hepatocellular carcinoma.World J Gastroenterol. 2010 Jan 28;16(4):418-24. doi: 10.3748/wjg.v16.i4.418. World J Gastroenterol. 2010. PMID: 20101765 Free PMC article. Review.
-
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.Oncotarget. 2017 Feb 21;8(8):14192-14220. doi: 10.18632/oncotarget.13929. Oncotarget. 2017. PMID: 28077782 Free PMC article. Review.
-
Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma.Br J Cancer. 2000 Feb;82(4):833-7. doi: 10.1054/bjoc.1999.1008. Br J Cancer. 2000. PMID: 10732755 Free PMC article.
-
Serum markers of hepatocellular carcinoma.Dig Dis Sci. 2010 Oct;55(10):2744-55. doi: 10.1007/s10620-010-1184-7. Epub 2010 Mar 26. Dig Dis Sci. 2010. PMID: 20339916 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical